Thank you, next: Takeda hands Ovid $196M cash to rein back in Phase III-ready seizure drug, reviving battered stock
Soticlestat made it.
Takeda is bringing the drug back into its fold more than four years after first entrusting the team at Ovid with the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
